Rahman Asadur, Fujisawa Yoshihide, Nakano Daisuke, Hitomi Hirofumi, Nishiyama Akira
Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Life Science Research Center, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Clin Exp Pharmacol Physiol. 2017 Apr;44(4):522-525. doi: 10.1111/1440-1681.12725.
Metabolic syndrome is often associated with disruption of circadian rhythm of systemic haemodynamics and cardiovascular disease. Experiments were conducted to investigate the effects of luseogliflozin, a selective SGLT2 inhibitor, on circadian rhythm of sympathetic nervous function and locomotor activity (LA) in metabolic syndrome rats. The difference in the low frequency component of systolic blood pressure between the dark and light period significantly increased in the luseogliflozin-treated SHRcp. LA also increased in the dark period compared with the light period following luseogliflozin treatment. These data suggest that circadian rhythm of sympathetic nervous function and LA is improved by luseogliflozin in metabolic syndrome rats, which may contribute to SGLT2 inhibitor-induced improvement of cardiovascular outcomes.
代谢综合征常与全身血流动力学昼夜节律紊乱及心血管疾病相关。进行实验以研究选择性SGLT2抑制剂鲁格列净对代谢综合征大鼠交感神经功能昼夜节律和运动活动（LA）的影响。在鲁格列净治疗的SHRcp大鼠中，收缩压低频成分在明暗周期之间的差异显著增加。鲁格列净治疗后，与明周期相比，暗周期的LA也增加。这些数据表明，鲁格列净可改善代谢综合征大鼠交感神经功能和LA的昼夜节律，这可能有助于SGLT2抑制剂改善心血管结局。
